Can menopause-related hormone shifts, low magnesium, and HPA-axis changes contribute to nighttime hyperarousal and fragmented sleep?

The menopausal transition is frequently accompanied by profound sleep disturbances, driven by intersecting neuroendocrine and biochemical pathways that trigger a state of nocturnal hyperarousal.

Mechanistic feedback loops

• HPA-axis hyperactivity: Impaired HPA-axis negative feedback elevates corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and cortisol levels. This directly drives central nervous system excitation, preventing the nervous system from transitioning into deep rest.
• Magnesium deficiency: Magnesium acts as a physiological NMDA receptor antagonist. Low magnesium status removes this voltage-dependent block, disinhibiting excitatory glutamatergic transmission and further impairing HPA-axis negative feedback, which elevates cortisol and ACTH.
• Hormonal shifts and catecholamine clearance: Menopause-related declines in estradiol reduce catechol-O-methyltransferase (COMT) transcription. This downregulates the enzymatic clearance of catecholamines (norepinephrine and dopamine), prolonging central sympathetic activation and increasing stress sensitivity, though direct clinical links to insomnia require further validation.

Sleep fragmentation and clinical implications

• Disrupted sleep architecture: The combination of glutamatergic over-activation, elevated cortisol, and impaired catecholamine clearance maintains a persistent "wired" state. This clinical hyperarousal prevents sustained slow-wave sleep, resulting in fragmented sleep architecture and frequent nocturnal awakenings.

Bottom line

• Nighttime hyperarousal and fragmented sleep during menopause are driven by a highly interactive network where low magnesium status and estrogen-mediated reductions in COMT transcription directly amplify HPA-axis hyperactivity and sympathetic tone.